Differential	O
Immunohistochemical	O
Profiles	B:C1979963
for	O
Distinguishing	O
Prostate	O
Carcinoma	I:C0600139
and	O
Urothelial	O
Carcinoma	I:C2145472
.	O

Differential	O
Immunohistochemical	O
Profiles	O
for	O
Distinguishing	O
Prostate	B:C0600139
Carcinoma	I:C0600139
and	O
Urothelial	O
Carcinoma	I:C2145472
.	O

Differential	O
Immunohistochemical	O
Profiles	O
for	O
Distinguishing	O
Prostate	O
Carcinoma	I:C0600139
and	O
Urothelial	B:C2145472
Carcinoma	I:C2145472
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
(	O
prostate	O
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	O
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	O
carcinoma	I:C2145472
(	O
urothelial	O
carcinoma	I:C2145472
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	O
adenocarcinoma	I:C0007112
(	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	O
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	O
carcinoma	I:C2145472
(	O
urothelial	O
carcinoma	I:C2145472
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	O
adenocarcinoma	I:C0007112
(	O
prostate	O
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	B:C0005682
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	O
carcinoma	I:C2145472
(	O
urothelial	O
carcinoma	I:C2145472
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	O
adenocarcinoma	I:C0007112
(	O
prostate	O
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	O
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	B:C2145472
carcinoma	I:C2145472
(	O
urothelial	O
carcinoma	I:C2145472
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	O
adenocarcinoma	I:C0007112
(	O
prostate	O
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	O
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	O
carcinoma	I:C2145472
(	O
urothelial	B:C2145472
carcinoma	I:C2145472
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	O
adenocarcinoma	I:C0007112
(	O
prostate	O
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	O
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	O
carcinoma	I:C2145472
(	O
urothelial	O
carcinoma	I:C2145472
)	O
infiltrating	B:C0332448
the	O
prostate	O
can	O
be	O
difficult	O
.	O

The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	O
adenocarcinoma	I:C0007112
(	O
prostate	O
adenocarcinoma	I:C0007112
)	O
involving	O
the	O
urinary	O
bladder	I:C0005682
and	O
high	O
-	O
grade	O
urothelial	O
carcinoma	I:C2145472
(	O
urothelial	O
carcinoma	I:C2145472
)	O
infiltrating	O
the	O
prostate	B:C0033572
can	O
be	O
difficult	O
.	O

However	O
,	O
making	O
this	O
distinction	O
is	O
clinically	O
important	O
because	O
of	O
the	O
different	O
treatment	B:C0087111
modalities	O
for	O
these	O
two	O
entities	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
,	O
111	O
cases	O
;	O
urothelial	O
carcinoma	I:C2145472
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	O
St.	I:C0019994
Mary	I:C0019994
's	I:C0019994
Hospital	I:C0019994
were	O
studied	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
prostate	O
adenocarcinoma	I:C0007112
,	O
111	O
cases	O
;	O
urothelial	B:C2145472
carcinoma	I:C2145472
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	O
St.	I:C0019994
Mary	I:C0019994
's	I:C0019994
Hospital	I:C0019994
were	O
studied	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
prostate	O
adenocarcinoma	I:C0007112
,	O
111	O
cases	O
;	O
urothelial	O
carcinoma	I:C2145472
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	B:C0019994
St.	I:C0019994
Mary	I:C0019994
's	I:C0019994
Hospital	I:C0019994
were	O
studied	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
prostate	O
adenocarcinoma	I:C0007112
,	O
111	O
cases	O
;	O
urothelial	O
carcinoma	I:C2145472
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	O
St.	I:C0019994
Mary	I:C0019994
's	I:C0019994
Hospital	I:C0019994
were	O
studied	B:C2603343
.	O

An	O
immunohistochemical	O
evaluation	B:C0474700
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	B:C0033572
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	B:C0041365
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	B:C1310550
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	B:C1310550
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	B:C1740167
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	B:C1740167
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	B:C0965053
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	B:C1505704
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	B:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	B:C0666209
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	B:C0227598
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	B:C0041365
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	B:C0908867
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	B:C1431519
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	B:C0145779
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	B:C1447472
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	B:C1307598
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	B:C1307598
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

An	O
immunohistochemical	O
evaluation	O
of	O
prostatic	O
markers	O
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
[	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
]	O
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
[	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
]	O
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
[	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-	O
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
[	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34	O
βE12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	I:C1307598
protein	I:C1307598
3	I:C1307598
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	B:C0027651
.	O

The	O
sensitivities	O
of	O
prostatic	B:C0033572
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	B:C0041365
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	B:C1310550
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	B:C1740167
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	B:C0965053
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	B:C1505704
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
prostate	O
adenocarcinoma	I:C0007112
were	O
100	O
%	O
for	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
83.8	O
%	O
for	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
91.9	O
%	O
for	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	I:C1505704
,	O
and	O
66.7	O
%	O
for	O
and	B:C0666209
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
.	O

However	O
,	O
the	O
urothelial	B:C0227598
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	B:C0041365
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	B:C0908867
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	B:C1431519
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	B:C0145779
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	B:C1447472
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	B:C1307598
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	B:C1446409
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	O
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
,	O
respectively	O
.	O

The	O
sensitivities	O
of	O
urothelial	B:C0227598
markers	O
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	B:C0041365
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
urothelial	B:C2145472
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	B:C0908867
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	B:C1431519
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	B:C0145779
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	B:C1447472
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
urothelial	O
carcinoma	I:C2145472
were	O
75.4	O
%	O
for	O
CK34	O
β	I:C0908867
E12	I:C0908867
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	B:C1307598
.	O

Conversely	O
,	O
the	O
prostatic	B:C0033572
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	B:C0041365
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	B:C1310550
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	B:C1740167
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	B:C0965053
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	B:C1505704
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	B:C0666209
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	B:C1446409
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	O
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
prostate	O
-	I:C1310550
specific	I:C1310550
membrane	I:C1310550
antigen	I:C1310550
,	O
prostate	O
acid	I:C1740167
phosphatase	I:C1740167
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
and	O
α-	I:C0666209
methylacyl	I:C0666209
coenzyme	I:C0666209
A	I:C0666209
racemase	I:C0666209
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
urothelial	B:C2145472
carcinoma	I:C2145472
s	O
,	O
respectively	O
.	O

Prostatic	B:C0033572
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	B:C0227598
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	B:C0041365
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	B:C1505704
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	B:C1431519
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	B:C0145779
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	B:C1307598
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	B:C2145472
carcinoma	I:C2145472
.	O

The	O
optimal	O
combination	O
of	O
prostatic	B:C0033572
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
pathologically	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	B:C0227598
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
pathologically	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	B:C0041365
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
pathologically	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	B:C0184511
the	O
ability	O
to	O
differentiate	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
pathologically	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	B:C1299581
to	O
differentiate	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
pathologically	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
prostate	B:C0007112
adenocarcinoma	I:C0007112
from	O
urothelial	O
carcinoma	I:C2145472
pathologically	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
prostate	O
adenocarcinoma	I:C0007112
from	O
urothelial	B:C2145472
carcinoma	I:C2145472
pathologically	O
.	O

